Interferon (IFN) therapy of early chronic myelogenous leukemia (CML) frequently produces partial or complete cytogenetic remission of the disease. Patients with complete cytogenetic remission often continue on therapy for several years with bone marrow showing only diploid (normal) metaphases. We studied hematopoiesis in five female patients with major cytogenetic remissions from CML during IFN therapy. Clonality analysis using the BstXl PGK gene polymorphism showed HRONIC MYELOGENOUS leukemia (CML) is a C disease characterized by acquisition of the Philadelphia (Phl) chromosomal translocation in early hematopoietic stem cells. Clonal expansion of late myeloid progenitor cells leads to a state of granulocytic hyperplasia in which most or all bone marrow metaphases contain the Phl chromosome. At the molecular level, the Phl may be identified by the formation of a chimeric fusion of the BCR and the c-ABL genes, resulting in a hybrid transcript and protein product (~2 l O ) .~-~
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The malignant transforming event in CML has been presumed to occur in a pluripotent stem cell on the basis of the following evidence: (1) Phl metaphases in erythroid and lymphoid as well as myeloid cell^^'^; (2) the development of blast crises of varying lineage phenotype (myeloid, erythroid, megakaryocytic, lymphoid-B, and lymphoid-T)""; and (3) the finding by various techniques that purified cells of different lineages are clonal.''-14 The lymphoid lineages have been of particular interest because of their divergence from the myeloid lines at an early stage of differentiation. Although there is evidence for B-and T-cell differentiation of Phl-positive progenitors, most polyclonal B-cell and almost all T-cell lines derived from CML patients have been Phl negative.6 Circulating T cells were found to be polyclonal in three patients examined by Fialkow et al."
Expansion of the Phl clone occurs concomitantly with suppression of the cytogenetically normal (diploid) hemopoietic tissue. Both in vitro manipulation^^^'^ and studies of clinical specimens after myelos~ppressive'~~'~ and a-interferon (a-IFN) the rap^'^,^^ have shown the persistence of Phl-negative progenitors. The long duration of the IFNinduced remissions shows that diploid stem cells may stably reconstitute hematopoiesis. Fialkow et a1 have provided evidence that many Phl-negative B cells in chronic-phase CML might be clonal.m This then would suggest that the bcr-ab1 rearrangement and Phl might be a second mutation in an already transformed clone.
IFN treatment of early-stage CML often produces disease remissions characterized by chimeric mixtures of normal with Phl-positive metaphase^.'^.'^ In a minority of these cases, the Phl clone is completely suppressed. This situation and the considerations discussed above have led to questions regarding the nature of hematopoiesis in cytogenetic remissions of CML. We analyzed the cells of CML in cytogenetic remissions for clonal or polyclonal hematopoietic cells using X-linked polymorphic markers. These studies show that cytogenetic remissions from the chronic phase of CML resulting from IFN and myelosuppressive therapy are polyclonal and thus may be derived from normal stem cells.
MATERIALS AND METHODS
All patients showed clinical findings typical of CML and at diagnosis had a predominance of Phl-positive metaphases in unstimulated bone marrow. Female patients were selected for informativeness for the phosphoglycerate kinase (PGK) Bgl I and BstXI polymorphic locus?' IFN was administered as d e~c r i b e d '~~'~~~~ on or according to institutional protocols.
The chromosome data was obtained from bone marrow aspirates from all of the patients in this study using routine cytogenetic methods.*' The samples were incubated over- A minimum of 25 well-spread Giemsa-banded metaphases were analyzed from each culture. Karyotypes were prepared on at least two metaphases of each cell type using the International System for Human Cytogenetic Nomenclature (ISN 1985).% Heparinized blood and, in some cases, bone marrow were obtained in the course of routine clinical sampling. Approval was obtained from the Institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki. Blood samples were separated by density gradient centrifugation on Ficoll-Hypaque into mononuclear (interface) and granulocyte (pellet) fractions.
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CLAXTON ET AL greater than 85% of nucleated cells were granulocytes (in most cases greater than 90%). The pellet was resuspended in NH,Cl 0.83% wt/vol and incubated at 37°C for 1 to 2 hours to lyse red cells. Genomic DNA was extracted by phenol followed by chloroform extractions. Bone marrow and, in some cases, whole blood was pelleted and DNA was extracted for blood fractions.
T cells were expanded from peripheral blood mononuclear cells or bone marrow as follows. Cells (0.5 to 2 x lo6) were cultured in wells of 24-well plates with starter medium (RPMI 1640) supplemented with phytohemagglutinin (PHA) 1% (M-form; GIBCO) and interleukin-2 (IL-2; recombinant human; Hoffman Laroche, Nutley, NJ) (100 UlmL). At 48 to 72 hours, the cultures were fed with growth medium (identical to starter medium but with PHA only 0.4%). Polyclonal T-cell lines were subsequently expanded by feeding at 24-to 72-hour intervals with growth medium. At days 14 to 21, the cells were counted in trypan blue 0.2%. Characteristically, cell numbers were 15-to 50-fold greater than at day 1 and viability was 80% to 96%. DNA was extracted as above.
For X-linked clonality analysis, DNA was digested as described by Voglestein et al?' Patients were screened for heterozygosity at the PGK locus with Bgl I digestion. Subsequently, clonal analysis was performed using BstXI." For bcr region rearrangement studies, 10 pg of DNA was digested with Bgl I1 and Xba I with 8 U of enzyme/kg DNA for 6 hours in the manufacturer's recommended buffer. DNA was separated by electrophoresis on 0.8% agarose gels. Gels were agitated in 0.5N NaOH, 1.5 mol/L NaCl for 30 minutes, followed by 45 minutes in 0.5 mol/L Tris, pH 7,3 mol/L NaCl. DNA was transferred to nylon (Hybond N; Amersham, Arlington Heights, IL) in 6X SSPE overnight. Membranes were vacuum-baked at 80°C for 2 hours before prehybridization in 6X SSPE, 1OX Denhart's solution, 0.5% sodium dodecyl sulfate (SDS) and 50 kg/mL salmon sperm DNA (ssDNA) at 65°C for 3 to 5 hours. Probes were labeled by random primingz (Amersham) and after 100°C denaturation were hybridized to membranes in 6X SSPE, 10% dextran sulfate, 0.5% SDS, and 50 +g/mL ssDNA at 65°C overnight. Final washes were in 0.1X SSPE and 0.5% SDS for 30 minutes at 60°C. The pSPT/PGKprobe was generously provided by Dr Voglestein. The universal bcr probe was purchased from Oncogene Sciences (Manhasset, NY).
Densitometry. A Joyce-Loeble (Oyster Bay, NY) Ephortec Chromoscan 3 densitometer was used for quantitative assessment of hybridization signals on PGK clonality gels. The larger allele has been designated allele 1, and the smaller allele 2. Lanes of DNA before Hpa I1 digestion (but after BstXI and Pst I) we have designated "A," while those after Hpa I1 digestion are refered to as "H." Thus for any given sample's analysis there are four relevant bands and four corresponding densitometric signals Al, A2, H1, and H2. The A lane is helpful for addressing possible technical difficulties with the sample. The calculation Al/(Al + A2) yields a figure that will be refered to as RIAl (for relative intensity of band Al). This value is similar to the calculated value "A' discussed by Nash et alZ6 and should be close to or equal to 0.50. A similar calculation for the Hpa 11-digested lanes H l / ( H l + H2) designated RMHl (relative methylation of H1) provides quantitative assessment of allelic methylation. Clonality studies were interpreted by previously published criteria" and after the evaluation of densitometric studies (above). BCR rearrangements were identified when bands of mobility differing from the germline were seen hybridizing in lanes of completely digested DNA.
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RESULTS
Samples from five patients with Phl-positive CML were studied during periods
Patient clinical characteristics.
of partial cytogenetic remission ( < 35% Phl-positive bone marrow metaphases)" or complete cytogenetic remission while on treatment with IFN. Patients 1,2,3, and 5 had all presented with typical Phl-positive CML and were all treated with IFN beginning in first chronic phase within 6 months of diagnosis. Patient 4 differed in having had two episodes of lymphoid blast crisis treated with cytotoxic agents before 3.5 years of partial cytogenetic remission. During this remission, the patient received sequential IFN-a and -y and cyclic therapy with vincristine, prednisone, methotrexate, and 6-mercaptopurine. Salient clinical features and maximal cytogenetic responses are given for each patient in Table 1 .
Before analyzing the patient materials, we determined the sensitivity of Southern blotting procedures used in this study. The clonal analysis of Voglestein et alZ1 was examined by mixing varying proportions of two DNA samples together before enzyme digestions. Sample A was known to have a PGK locus methylation skew towards allele 2 (ie, with allele 2 nearly completely methylated), while sample B was skewed to allele 1. Results are shown in Fig 1A. Admixture of one specimen to the other in a 20230 ratio appears clearly detectable. To verify the quantitative nature of the signals seen for individual mixes, densitometry was performed. Values for RIAl and RMHl are given for each DNA mixture in Table 2 . RMHl values are plotted relative to % BCR region rearrangement was similarly studied by mixing varying proprotions of a sample known to consist of bcr rearranged cells (CML marrow in untreated chronic phase) with a normal granulocyte DNA. Figure 1B shows that our procedure detects an addition of 20% rearranged DNA to the normal sample. Table 3 . For patient 2, a pretreatment bone marrow sample is shown (Fig 3B, lanes 1  and 2) . Clonal hematopoiesis is clearly shown at that point (ie, allele 1 appears unmethylated despite the DNA overloading). This finding is confirmed by densitometry as RMHl is 0 for this early specimen. In this individual, as in patients 1 and 3, remission samples show a skewed distribution of methylation of alleles with a majority of allele 2 (the lower allele) being methylated. In all cases, however, autologous T cells show methylation similar to the remission samples, suggesting that the methylation skew is present in constitutional (normal) tissues. As seen in Table  3 , densitometry confirms that for any given patient RMHl values of all remission samples and T cells are within a close range. The degree of variation is expected given the results of densitometry performed on the standardization mixtures. It must be noted that our technique is not precise enough to exclude a 20% to 30% clonal population coexisting with the nonclonal cells. Figure 4 shows these results. As expected, the pretreatment sample available for patient 2 shows bcr rearrangement. Samples taken during IFN-
BCR region studies.
induced remission show only germline bands for this patient and patients 1,3, and 5. Only patient 4 is shown to have any bcr region rearrangement in samples obtained during IFN-induced remission. This finding is consistent with the fact that only a partial cytogenetic remission was observed in the period of sample collection and that Phl-positive (bcr rearranged) cells were present in these samples.
DISCUSSION
As our data show that conversion from clonal to polyclonal hematopoiesis occurs with IFN-induced replacement of Phl-positive hematopoiesis by diploid cells, they give no support to the suggestion of a two-step pathogenesis of CML. Indeed, if a clonal Phl-negative process antedates the development of the Phl-positive hematopoiesis," then IFN must result in the suppression of most of this earliest clonal population. It must be noted that a population (up to approximately 30%) of clonal cells could be missed by our analysis. For such a population to exist in our patients it For personal use only. on August 30, 2017. by guest www.bloodjournal.org From would have to be less IFN sensitive than its suppressed Ph 1 -positive progeny.
Four of the five patients we have studied exhibited complete or near complete suppression of Phl-positive progenitors. The cytogenetic studies in these four patients performed at or near the time of blood sampling showed no or very few abnormal metaphases. Examination of the bcr region for rearrangement has shown only germline bands in both Bgl I1 and Xbu I digests. Under these conditions, greater than 95% of rearrangements of this region are detected." As these studies would have detected a 20% admixture of bcr rearranged (Phl-positive) cells, our bcr studies in these four patients are in agreement with the cytogenetic findings. In all these patients granulopoiesis In patient 4, the cytogenetic remission was less complete than that of our other patients. This patient also differed from the others in that she had sustained two episodes of blast crisis and had received considerable cytotoxic chemotherapy. Two samples, one of whole blood and the other of granulocytes, show a clear nonclonal pattern in this patient. These same samples contain bcr-rearranged sequences. Thus, at the times of sampling, this patient's hematopoiesis arose from a mixture of normal nonclonal progenitors and bcr-rearranged (Phl-positive) progenitors. T cells expanded from this individual (and all the other patients studied) showed no evidence of bcr rearrangement. This finding is consistent with previous reports of Phl-negative T-cell lines expanded from Phl-positive CML patients.
Previous studies have suggested that the vast majority of circulating T cells are diploidR and n~nclonal'~ in CML.
Both the visual and densitometric assessment of our clonal studies strongly suggests a similar progenitor pool for T cells and granulopoiesis during IFN therapy in our patients. Nonetheless, we are not able to exclude the possibility that the control T-cell preparations used in this study were partially clonal (ie, derived in part from a clonal Phlnegative progenitor). Were this to be the case and even in the absence of a normal "control" tissue, the presence of a "nonclonal" pattern (two partially methylated alleles) in clonal studies of granulocytes indicates that granulopoiesis is at least partially nonclonal. (Fig 2A lane 1) and 4 (Fig 28 lanes 1 and 2) .
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